Akashi Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Akashi Therapeutics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10955
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:19
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Akashi Therapeutics Inc (Akashi Therapeutics), formerly DART Therapeutics Inc is a clinical stage biopharmaceutical company develops treatment for duchenne muscular dystrophy (DMD) and other rare pediatric diseases. The company provides pipeline portfolio such as HT-100, a small molecule drug candidate for the reduction of fibrosis and inflammation and to promote healthy muscle fiber regeneration in DMD patients; DT-200, an oral selective androgen receptor modulator (SARM) for the treatment of multiple neuromuscular diseases; and AT-300 is a modified form of a peptide obtained for the venom of the Chilean Rose Tarantula that can be used to balance the calcium levels in the muscle that leads to loss of function in DMD patients. Akashi Therapeutics is headquartered in Cambridge, Massachusetts, the US.

Akashi Therapeutics Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Akashi Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Akashi Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Akashi Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Akashi Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Akashi Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Akashi Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 10
Asset Purchase 10
Akashi Therapeutics Acquires Global Rights to GsMTx-4 from Tonus Therapeutics 10
Dart Therapeutics Acquires Rights to SARM Drug Candidate from Galapagos 11
Venture Financing 12
Halo Therapeutics Raises USD1.1 Million in Venture Financing 12
Partnerships 13
Grunenthal Enters into Co-Development Agreement with Akashi Therapeutics 13
Dart Therapeutics And Biovista Enter Into Research Agreement 14
Akashi Therapeutics Inc – Key Competitors 15
Akashi Therapeutics Inc – Key Employees 16
Akashi Therapeutics Inc – Locations And Subsidiaries 17
Head Office 17
Recent Developments 18
Product News 18
01/05/2017: Akashi Therapeutics Provides Update on AT-300 18
Appendix 19
Methodology 19
About GlobalData 19
Contact Us 19
Disclaimer 19

List of Tables
Akashi Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts 2
Akashi Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Akashi Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Akashi Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Akashi Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Akashi Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Akashi Therapeutics Acquires Global Rights to GsMTx-4 from Tonus Therapeutics 10
Dart Therapeutics Acquires Rights to SARM Drug Candidate from Galapagos 11
Halo Therapeutics Raises USD1.1 Million in Venture Financing 12
Grunenthal Enters into Co-Development Agreement with Akashi Therapeutics 13
Dart Therapeutics And Biovista Enter Into Research Agreement 14
Akashi Therapeutics Inc, Key Competitors 15
Akashi Therapeutics Inc, Key Employees 16

List of Figures
Akashi Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Akashi Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Akashi Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Akashi Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Akashi Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Akashi Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Akashi Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Akashi Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Akashi Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Okamoto Industries, Inc.:企業の戦略・SWOT・財務情報
    Okamoto Industries, Inc. - Strategy, SWOT and Corporate Finance Report Summary Okamoto Industries, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Cap Gemini S.A.:戦略・SWOT・企業財務分析
    Cap Gemini S.A. - Strategy, SWOT and Corporate Finance Report Summary Cap Gemini S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Sinoma International Engineering Co Ltd:企業の戦略・SWOT・財務情報
    Sinoma International Engineering Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Sinoma International Engineering Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT a …
  • Exosome Diagnostics Inc:企業の製品パイプライン分析
    Summary Exosome Diagnostics Inc (Exosome Diagnostics) is a provider of diagnostic solutions. The company develops, designs, manufactures and markets biofluid-based molecular diagnostic tests and products for use in personalized medicine. Exosome Diagnostics’ services comprise miRNA profiling, mRNA p …
  • McKesson Corp (MCK):医療機器:M&Aディール及び事業提携情報
    Summary McKesson Corp (McKesson) is a provider of healthcare services and information technology solutions. It distributes pharmaceuticals, medical equipment, and health and beauty care products in North America and overseas. The company also develops and provides decision support software and syste …
  • Orly International, Inc.:企業の戦略・SWOT・財務分析
    Orly International, Inc. - Strategy, SWOT and Corporate Finance Report Summary Orly International, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • CME Group Inc:企業のM&A・事業提携・投資動向
    CME Group Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's CME Group Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments …
  • Tissue Genesis Inc-医療機器分野:企業M&A・提携分析
    Summary Tissue Genesis Inc (TGI) is a biotechnology company that provides services in the area of tissue engineering and cell therapy solutions. The company’s products include tissue genesis cell isolation system and icellator cell isolation system. It offers services such as repair restore and reju …
  • Medicago Inc:企業のM&A・事業提携・投資動向
    Medicago Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Medicago Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, …
  • Marathon Petroleum Corporation:企業の戦略・SWOT・財務情報
    Marathon Petroleum Corporation - Strategy, SWOT and Corporate Finance Report Summary Marathon Petroleum Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • MAXONS Restorations Inc:企業の戦略的SWOT分析
    MAXONS Restorations Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • T-Mobile Netherlands Holding B.V.:企業の戦略的SWOT分析
    T-Mobile Netherlands Holding B.V. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major p …
  • Teradyne Inc (TER):企業の財務・戦略的SWOT分析
    Teradyne Inc (TER) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Euroclear Plc:企業の戦略・SWOT・財務分析
    Euroclear Plc - Strategy, SWOT and Corporate Finance Report Summary Euroclear Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • The Timken Company:企業の戦略・SWOT・財務情報
    The Timken Company - Strategy, SWOT and Corporate Finance Report Summary The Timken Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Landauer Inc (LDR):企業の財務・戦略的SWOT分析
    Summary Landauer Inc (Landauer), a subsidiary of Fortive Corp, is a medical device company that manufactures and distributes integrated radiation safety products. The company provides professional medical physics, occupational radiation monitoring, and medical products. Its products include dosimete …
  • Entasis Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Entasis Therapeutics Inc (Entasis) is a drug development company that discovers and develops anti-infective therapies for drug-resistant bacterial infections. The company’s pipeline products include ETX2514, ETX0282, ETX0914 and Zoliflodacin. Its ETX2514 is a potent inhibitor of class A, C, …
  • Advanced Biological Laboratories SA-製薬・医療分野:企業M&A・提携分析
    Summary Advanced Biological Laboratories SA (ABL) is a healthcare information technology company that provides integrated software solutions for personalised medicine. The company’s products include improving disease management software, project management software, cumulative reporting and related …
  • Strike Energy Ltd (STX):企業の財務・戦略的SWOT分析
    Summary Strike Energy Ltd (Strike Energy) is an oil and gas exploration and development company that explores, produces, and develops shale oil and gas. The company provides properties such as Eagle Ford Shale, Permian Basin, Cooper Basin, gulf coast conventional, and others. It has exploration and …
  • Habib Insurance Co Ltd (HICL):企業の財務・戦略的SWOT分析
    Habib Insurance Co Ltd (HICL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆